Who founded Lipidiopharma?

Lipidiopharma was founded by James Mackay in 2019.

Who are Lipidiopharma's investors?

Lipidiopharma's investors include 3E Bioventures Capital.

How much funding has Lipidiopharma raised?

Lipidiopharma has disclosed $4.6M raised across 1 round.

Where is Lipidiopharma headquartered?

Lipidiopharma is headquartered in San Diego, US.

Lipidiopharma

San Diego, US · Founded 2019 · 1 known investors

Find your way into Lipidiopharma

Paths you didn't know you had: your email and LinkedIn already hold routes to the Lipidiopharma team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Lipidio Pharma is a drug development company that acquires molecules with unrealized therapeutic potential and advances them through preclinical and clinical development toward approval or exit. It is currently developing therapeutics for two indications, obesity and sebaceous hyperplasia.

Biotech Healthtech

Founders & leadership

Lipidiopharma was founded in 2019 by James Mackay.

James MackayCo-Founder

David BulloughNamed on SEC filing

Daniel PetreeNamed on SEC filing

J. Gordon FoulkesNamed on SEC filing

Investors · 1

3E Bioventures Capitallisted by 3E Bioventures CapitalPalo Alto

How we know: the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$4.6M disclosed across 1 round · 2019

▶$4.6MraisedNov 2019 · 58 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

David BulloughDirector
Daniel PetreeDirector
J. Gordon FoulkesExecutive Officer, Director

Offering amount: $12M
Amount sold: $4.6M
Sales commissions: $462.3K
Placement agents: Maxim Group LLC
First sale: Nov 2019
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 8

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

AdipopharmaAdipoPharma is a biotech company developing therapies based on the endocrine biology of adipose tissue and targeted rare genetic disorders. Founded in 2022 (formerly ALMS Therapeutics), its work relates to metabolic diseases such as diabetes and obesity.

Novo NordiskNovo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies. It serves patients and healthcare markets globally.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

RadiuspharmRadius is a pharmaceutical company that provides funding through Investigator Initiated Study grants and independent Medical Education grants supporting clinical research and continuing medical education for healthcare professionals in therapeutic areas related to its products.

LigandLigand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies. The company maintains a diversified portfolio of royalty assets across oncology, rare diseases, and other therapeutic areas, and licenses proprietary technology platforms to pharmaceutical manufacturers.

DiasomeDiasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases. The company focuses on translating therapeutic insights to restore metabolic function using endogenous mechanisms.

Parabilis MedicinesHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.

Companies working in the same space as Lipidiopharma.

Frequently asked questions

What does Lipidiopharma do?: Lipidio Pharma is a drug development company that acquires molecules with unrealized therapeutic potential and advances them through preclinical and clinical development toward approval or exit. It is currently developing therapeutics for two indications, obesity and sebaceous hyperplasia.
Who founded Lipidiopharma?: Lipidiopharma was founded by James Mackay in 2019.
Who are Lipidiopharma's investors?: Lipidiopharma's investors include 3E Bioventures Capital.
How much funding has Lipidiopharma raised?: Lipidiopharma has disclosed $4.6M raised across 1 round.
Where is Lipidiopharma headquartered?: Lipidiopharma is headquartered in San Diego, US.